157 related articles for article (PubMed ID: 36283223)
1. Pharmacological inhibition of AIMP2 aggregation attenuates α-synuclein aggregation and toxicity in Parkinson's disease.
Shin JY; Lee B; Ham S; Kim JH; Kim H; Kim H; Jo MG; Kim HJ; Park SW; Kweon HS; Kim YJ; Yun SP; Lee Y
Biomed Pharmacother; 2022 Dec; 156():113908. PubMed ID: 36283223
[TBL] [Abstract][Full Text] [Related]
2. Amyloid-like oligomerization of AIMP2 contributes to α-synuclein interaction and Lewy-like inclusion.
Ham S; Yun SP; Kim H; Kim D; Seo BA; Kim H; Shin JY; Dar MA; Lee GH; Lee YI; Kim D; Kim S; Kweon HS; Shin JH; Ko HS; Lee Y
Sci Transl Med; 2020 Nov; 12(569):. PubMed ID: 33177178
[TBL] [Abstract][Full Text] [Related]
3. Synthetic Peucedanocoumarin IV Prevents α-Synuclein Neurotoxicity in an Animal Model of Parkinson's Disease.
Kim H; Maeng HJ; Kim JH; Yoon JH; Oh Y; Paek SM; Lee Y
Int J Mol Sci; 2022 Aug; 23(15):. PubMed ID: 35955753
[TBL] [Abstract][Full Text] [Related]
4. 14-3-3 mitigates alpha-synuclein aggregation and toxicity in the in vivo preformed fibril model.
Underwood R; Gannon M; Pathak A; Kapa N; Chandra S; Klop A; Yacoubian TA
Acta Neuropathol Commun; 2021 Jan; 9(1):13. PubMed ID: 33413679
[TBL] [Abstract][Full Text] [Related]
5. Lewy body-associated proteins: victims, instigators, or innocent bystanders? The case of AIMP2 and alpha-synuclein.
Lashuel HA; Novello S
Neurobiol Dis; 2021 Aug; 156():105417. PubMed ID: 34102275
[TBL] [Abstract][Full Text] [Related]
6. Advanced human iPSC-based preclinical model for Parkinson's disease with optogenetic alpha-synuclein aggregation.
Kim MS; Ra EA; Kweon SH; Seo BA; Ko HS; Oh Y; Lee G
Cell Stem Cell; 2023 Jul; 30(7):973-986.e11. PubMed ID: 37339636
[TBL] [Abstract][Full Text] [Related]
7. A novel glucosylceramide synthase inhibitor attenuates alpha synuclein pathology and lysosomal dysfunction in preclinical models of synucleinopathy.
Cosden M; Jinn S; Yao L; Gretzula CA; Kandebo M; Toolan D; Hatcher NG; Ma L; Lemaire W; Adam GC; Burlein C; Minnick C; Flick R; Watt ML; Mulhearn J; Fraley M; Drolet RE; Marcus JN; Smith SM
Neurobiol Dis; 2021 Nov; 159():105507. PubMed ID: 34509608
[TBL] [Abstract][Full Text] [Related]
8. LncRNA SNHG1 promotes α-synuclein aggregation and toxicity by targeting miR-15b-5p to activate SIAH1 in human neuroblastoma SH-SY5Y cells.
Chen Y; Lian YJ; Ma YQ; Wu CJ; Zheng YK; Xie NC
Neurotoxicology; 2018 Sep; 68():212-221. PubMed ID: 29217406
[TBL] [Abstract][Full Text] [Related]
9. Small molecule inhibits α-synuclein aggregation, disrupts amyloid fibrils, and prevents degeneration of dopaminergic neurons.
Pujols J; Peña-Díaz S; Lázaro DF; Peccati F; Pinheiro F; González D; Carija A; Navarro S; Conde-Giménez M; García J; Guardiola S; Giralt E; Salvatella X; Sancho J; Sodupe M; Outeiro TF; Dalfó E; Ventura S
Proc Natl Acad Sci U S A; 2018 Oct; 115(41):10481-10486. PubMed ID: 30249646
[TBL] [Abstract][Full Text] [Related]
10. Monoamine Oxidase-B Inhibition Facilitates α-Synuclein Secretion
Nakamura Y; Arawaka S; Sato H; Sasaki A; Shigekiyo T; Takahata K; Tsunekawa H; Kato T
J Neurosci; 2021 Sep; 41(35):7479-7491. PubMed ID: 34290084
[TBL] [Abstract][Full Text] [Related]
11. Adenosine A1 receptor ligands bind to α-synuclein: implications for α-synuclein misfolding and α-synucleinopathy in Parkinson's disease.
Jakova E; Moutaoufik MT; Lee JS; Babu M; Cayabyab FS
Transl Neurodegener; 2022 Feb; 11(1):9. PubMed ID: 35139916
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological characterization of the small molecule 03A10 as an inhibitor of α-synuclein aggregation for Parkinson's disease treatment.
Wang Q; Yao S; Yang ZX; Zhou C; Zhang Y; Zhang Y; Zhang L; Li JT; Xu ZJ; Zhu WL; Zhang NX; Ye Y; Feng LY
Acta Pharmacol Sin; 2023 Jun; 44(6):1122-1134. PubMed ID: 36627343
[TBL] [Abstract][Full Text] [Related]
13. Phenotypic manifestation of α-synuclein strains derived from Parkinson's disease and multiple system atrophy in human dopaminergic neurons.
Tanudjojo B; Shaikh SS; Fenyi A; Bousset L; Agarwal D; Marsh J; Zois C; Heman-Ackah S; Fischer R; Sims D; Melki R; Tofaris GK
Nat Commun; 2021 Jun; 12(1):3817. PubMed ID: 34155194
[TBL] [Abstract][Full Text] [Related]
14. VPS35 regulates parkin substrate AIMP2 toxicity by facilitating lysosomal clearance of AIMP2.
Yun SP; Kim H; Ham S; Kwon SH; Lee GH; Shin JH; Lee SH; Ko HS; Lee Y
Cell Death Dis; 2017 Apr; 8(4):e2741. PubMed ID: 28383562
[TBL] [Abstract][Full Text] [Related]
15. A glutaminyl cyclase-catalyzed α-synuclein modification identified in human synucleinopathies.
Hartlage-Rübsamen M; Bluhm A; Moceri S; Machner L; Köppen J; Schenk M; Hilbrich I; Holzer M; Weidenfeller M; Richter F; Coras R; Serrano GE; Beach TG; Schilling S; von Hörsten S; Xiang W; Schulze A; Roßner S
Acta Neuropathol; 2021 Sep; 142(3):399-421. PubMed ID: 34309760
[TBL] [Abstract][Full Text] [Related]
16. Anti-α-synuclein c-terminal antibodies block PFF uptake and accumulation of phospho-synuclein in preclinical models of Parkinson's disease.
Brendza R; Gao X; Stark KL; Lin H; Lee SH; Hu C; Cai H; DiCara D; Hsiao YC; Ngu H; Foreman O; Baca M; Dohse M; Fortin JP; Corpuz R; Seshasayee D; Easton A; Ayalon G; Hötzel I; Chih B
Neurobiol Dis; 2023 Feb; 177():105969. PubMed ID: 36535551
[TBL] [Abstract][Full Text] [Related]
17. 14-3-3 Proteins Reduce Cell-to-Cell Transfer and Propagation of Pathogenic α-Synuclein.
Wang B; Underwood R; Kamath A; Britain C; McFerrin MB; McLean PJ; Volpicelli-Daley LA; Whitaker RH; Placzek WJ; Becker K; Ma J; Yacoubian TA
J Neurosci; 2018 Sep; 38(38):8211-8232. PubMed ID: 30093536
[TBL] [Abstract][Full Text] [Related]
18. CD8 T cell nigral infiltration precedes synucleinopathy in early stages of Parkinson's disease.
Galiano-Landeira J; Torra A; Vila M; Bové J
Brain; 2020 Dec; 143(12):3717-3733. PubMed ID: 33118032
[TBL] [Abstract][Full Text] [Related]
19. NK cells clear α-synuclein and the depletion of NK cells exacerbates synuclein pathology in a mouse model of α-synucleinopathy.
Earls RH; Menees KB; Chung J; Gutekunst CA; Lee HJ; Hazim MG; Rada B; Wood LB; Lee JK
Proc Natl Acad Sci U S A; 2020 Jan; 117(3):1762-1771. PubMed ID: 31900358
[TBL] [Abstract][Full Text] [Related]
20. Activation of β-Glucocerebrosidase Reduces Pathological α-Synuclein and Restores Lysosomal Function in Parkinson's Patient Midbrain Neurons.
Mazzulli JR; Zunke F; Tsunemi T; Toker NJ; Jeon S; Burbulla LF; Patnaik S; Sidransky E; Marugan JJ; Sue CM; Krainc D
J Neurosci; 2016 Jul; 36(29):7693-706. PubMed ID: 27445146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
